Molecular Partners AG
NASDAQ:MOLNBiotechnology
+$0.03 today
- Market cap
- $100.28M
- Beta
- 0.71
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.55
Volume 0.00M
Average 0.00M
MOLN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Molecular Partners AGNASDAQ: MOLN
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 3.5% from a year ago
Cash & equivalents stood at CHF 78.53M at the end of Q1 FY2026, down 3.5% from a year earlier and down 5.0% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.
Context
- Cash & equivalents amounted to 89.9% of total assets at the end of Q1 FY2026, up 32.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -3.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
CHF · from the balance sheet
- Latest · FY2025
- 82.65M CHF
- Year-over-year change
- +29.4%
- 4-year CAGR
- +3.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 82.65M | +29.4% |
| FY2024 | 2024-12-31 | 63.87M | -5.1% |
| FY2023 | 2023-12-31 | 67.31M | -23.5% |
| FY2022 | 2022-12-31 | 87.95M | +22.5% |
| FY2021 | 2021-12-31 | 71.81M | — |
Cash & Equivalents vs competitors
How MOLN compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -3.5% is the 5th highest of 9, against a peer median of -4.0%.
- Cash & equivalents amounts to 89.9% of total assets for MOLN, versus a peer median of 22.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 78.53M CHF | -3.5% | -2.0% | 89.9% | |
| Mar 2026 | $76.96M USD | +102.7% | -24.7% | 32.1% | |
| Mar 2026 | $71.32M USD | +58.2% | +112.3% | 36.8% | |
| Mar 2026 | $42.15M USD | -3.4% | -30.7% | 27.0% | |
| Mar 2026 | $27.36M USD | -48.0% | +1.9% | 7.4% | |
| Mar 2026 | $26.05M USD | +37.8% | +18.8% | 18.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $14.95M USD | -18.5% | +33.5% | 65.9% |
| Mar 2026 | $9.64M USD | -4.6% | -11.7% | 18.6% | |
| Mar 2026 | $8.54M USD | -64.5% | +2.2% | 17.4% | |
| Peer median (excluding MOLN) | — | -4.0% | +2.1% | 22.8% | |
Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 71.81M | 87.95M | 67.31M | 63.87M | 82.65M |
| Short-term Investments | 61M | 161.2M | 119.58M | 85.57M | 10.41M |
| Net Receivables | 25.73M | 1.7M | 1.75M | 286K | 1.91M |
| Inventory | 2 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 2.31M | (1K) |
| Total Current Assets | 164.19M | 254.75M | 192.46M | 154.28M | 96.88M |
| Property, Plant & Equipment (Net) | 8.15M | 7.24M | 5.68M | 4.2M | 5.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 330K | 271K | 212K | 49K | 2K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1K | (7.51M) | 0 | 0 | 0 |
| Total Non-current Assets | 8.48M | 7.51M | 5.89M | 4.25M | 5.23M |
| Total Assets | 172.67M | 262.26M | 198.35M | 158.53M | 102.11M |
| Account Payables | 4.86M | 997K | 410K | 679K | 937K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 855K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 28.31M | 6.41M | 4.33M | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 1K |
| Total Current Liabilities | 46.87M | 17.25M | 14.42M | 10.79M | 11.03M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 6.93M | 3.64M | 0 | 0 | 0 |
| Other Non-current Liabilities | 6.74M | 2.55M | 5.06M | 4.88M | 8.31M |
| Total Non-current Liabilities | 18.51M | 9.84M | 7.51M | 6.11M | 10.75M |
| Total Liabilities | 65.38M | 27.09M | 21.92M | 16.89M | 21.77M |
| Common Stock | 3.23M | 3.6M | 3.64M | 4.04M | 4.04M |
| Retained Earnings | (250.95M) | (127.78M) | (191.76M) | (246.29M) | (311.75M) |
| Accumulated OCI | 0 | (981K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | (0) | (0) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 107.29M | 235.17M | 176.43M | 141.64M | 80.33M |
| Total Debt | 6.04M | 4.85M | 3.65M | 2.44M | 3.64M |
| Net Debt | (65.77M) | (83.1M) | (63.66M) | (61.43M) | (79.01M) |
Molecular Partners AG
NASDAQ:MOLN
Intrinsic Alpha fair value
Locked
Current Price
$2.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.